RxDoctor Payments Data

David Jeong

Allergy & Immunology · White Plains, NYNPI 1912023565

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,726 of the $68,386 with a category attached, or 69.8%. 28 manufacturers reported payments, led by AstraZeneca at 55.6% of the total. Reporting peaked in 2024 at $34,137 and has fallen 80.4% since, to $6,697 in 2025. Among allergy & immunology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,386in general payments, 2019–2025

Across 422 payments — averaging $162.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$38K
  • Blueprint Medicines Corporation$10K
  • Novartis$7K
  • Amgen$4K
  • Sanofi$3K
  • Biocryst US Sales Co., LLC$983
  • plus $4K from 22 others
$322,405in research payments, 2019–2025

Across 38 payments — averaging $8484.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aimmune Therapeutics, Inc.$118K
  • Blueprint Medicines Corporation$116K
  • Novartis$88K

What the payments were for

  • Consulting fees$8,12412%
  • Speaking & faculty fees$47,72670%
  • Travel & lodging$2,5694%
  • Food & beverage$9,90414%
  • Education$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,386 in reported general payments places this provider in the 90th percentile of 320 allergy & immunology providers in New York.

See all allergy & immunology providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,832
Ipratropium Bromide31$1,527
Albuterol Sulfate HfaAlbuterol Sulfate29$668
Montelukast Sodium15$208
Prednisone20$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$819$13,83219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 320 allergy & immunology providers in New York.

Other allergy & immunology in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →